Clostridium difficile toxin in chronic idiopathic colitis.
Clostridium difficile toxin was isolated from the stools of three patients with chronic idiopathic colitis. Two patients were known to have chronic idiopathic colitis before Cl difficile toxin was isolated. The third patient was subsequently found to have ulcerative colitis after presentation with Cl difficile toxin in the stool. Two patients were on sulphasalazine at the time of diagnosis of Cl difficile infection and one had taken sulphasalazine two months previously. Only one patients had antibiotic exposure and that was at least three months before presentation. In each patient, treatment with vancomycin was accompanied by symptomatic improvement and disappearance of the toxin. The underlying colitis remained unaffected. In patients with inflammatory bowel disease in relapse, the presence of Cl difficile toxin should be sought as this may be a factor in the relapse. In any patient presenting with diarrhoea, the presence of Cl difficile toxin may obscure the presence of underlying inflammatory bowel disease.
D000328:Adult; D001426:Bacterial Proteins; D001427:Bacterial Toxins / Q000302:isolation & purification*; D002908:Chronic Disease; D003013:Clostridium / Q000378:metabolism*; D003015:Clostridium Infections / Q000150:complications; D003092:Colitis / Q000209:etiology / Q000378:metabolism*; D003093:Colitis, Ulcerative / Q000209:etiology; D003424:Crohn Disease / Q000378:metabolism; D003967:Diarrhea / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D012460:Sulfasalazine / Q000009:adverse effects; D014640:Vancomycin / Q000009:adverse effects
D001426:Bacterial Proteins; D001427:Bacterial Toxins; C031815:toxB protein, Clostridium difficile; D012460:Sulfasalazine; D014640:Vancomycin